Skip to content

    Acutaas Chemical

    ACUTAAS
    Healthcare·2 May 2025
    Management Summary

    Acutaas Chemical (formerly Ami Organics Limited) reported a landmark FY25, crossing INR1,000 crore in revenue with a 40.3% YoY growth. Q4 FY25 saw robust performance with revenue up 37.1% YoY and EBITDA margin expanding significantly to 27.5%. The company announced its rebranding to Acutaas Chemicals Limited, reflecting its diversified specialty chemicals vision. While facing global economic uncertainties and subdued demand in some segments, management remains optimistic about continued growth, driven by CDMO business, new electrolyte additive production, and recovery in the semiconductor segment, all while maintaining a debt-free balance sheet.

    Highlights

    8
    • FY25 Revenue: INR1,006.9 crores, up 40.3% YoY (Naresh Patel, CMD)

    • Q4 FY25 Revenue: INR308.5 crores, up 37.1% YoY (Bhavin Shah, CFO)

    • Q4 FY25 EBITDA Margin: 27.5%, expanded 835 bps YoY (Bhavin Shah, CFO)

    • Q4 FY25 PAT: INR62.7 crores, grew almost 2.5x YoY (Bhavin Shah, CFO)

    • FY25 PAT: INR160.4 crores, almost double YoY (Bhavin Shah, CFO)

    • Working capital improved to 114 days in FY25 from 116 days in FY24 (Bhavin Shah, CFO)

    • 10.8 MW solar plant commissioned, expected to deliver substantial annual cost savings (Abhishek Patel, VP Strategy)

    • Company is debt-free and not expecting any debt in the next year (Management)

    Concerns

    6
    • Global economic uncertainty and shifting geopolitical dynamics (Naresh Patel, CMD)

    • Unfolding U.S. tariff framework for chemicals, potentially impacting raw material and finished goods prices (Naresh Patel, CMD)

    • Moderate demand for electric vehicles and delays in new battery cell capacity (Naresh Patel, CMD)

    • Subdued demand for legacy semiconductors (Naresh Patel, CMD)

    • Specialty Chemicals segment reported flattish revenue of INR36 crores in Q4 FY25 and INR153 crores (2% growth) for FY25 due to degrowth in BFC business (Abhishek Patel, VP Strategy)

    • Q1 is typically the weakest quarter with softer H1 margins due to lower top line (Naresh Patel, CMD)

    What Changed1

    vs Q2 FY26

    Guidance items11 → 9 (-2)
    Key financials

    Metrics

    11

    Periods

    2

    Q4 FY25

    7
    • Revenue
      ₹308.5 Cr
      YoY+37.1%QoQ+12.2%
    • Gross Profit
      ₹146 Cr
      YoY+62.3%
    • Gross Margin
      47.3%
      YoY+7.3%QoQ+1.1%
    • EBITDA
      ₹85 Cr
      YoY+99%
    • EBITDA Margin
      27.5%
      YoY+8.3%QoQ+2.6%

    FY25

    4
    • Revenue
      ₹1,006.9 Cr
      YoY+40.3%
    • EBITDA
      ₹232.1 Cr
      YoY+80.6%
    • PAT
      ₹160.4 Cr
      YoY+99%
    • Cash Flow from Operations
      ₹118 Cr

    Segment breakdown

    • Pharmaceutical Intermediates₹273 Cr88.3%
    • Specialty Chemicals₹36 Cr11.7%
    Donut· Share of Revenue (Q4 FY25)

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    ₹200 crores

    through QIP proceeds and internal accruals of FY '25

    Debt

    Gross ₹0 crores · Net ₹0 crores · 0.0x EBITDA

    Liquidity

    Cash ₹249 crores

    Sufficient cash on hand to fund FY26 capex through QIP proceeds and internal accruals of FY25.

    Guidance & targets

    9
    CategoryTargetPriority
    Revenue
    Revenue Growth
    25%
    High
    Profitability
    Margin Improvement
    further improvements
    High
    Profitability
    EBITDA Margin
    higher than 23%
    High
    CDMO Business
    CDMO Revenue
    INR1,000 crores
    High
    Electrolyte Additives
    Production Commencement
    commence production
    High
    Electrolyte Additives
    Capacity
    2,000 metric ton per VC and 2,000 metric ton for FEC
    High
    Electrolyte Additives
    Optimum Capacity Utilization
    optimum capacity utilization
    Medium
    Solar Power
    Annual Cost Savings
    INR16 crores to INR18 crores
    High
    Specialty Chemicals
    Margin Improvement
    16% to 17%
    Medium

    Electrolyte Additives Production Commencement

    H2 FY26
    CurrentScheduled for H2 FY26
    TargetProduction commencement at Jhagadia site

    Why it matters

    This new business segment is a key growth driver, and its operational start is crucial for future revenue streams.

    Additionally, our electrolyte additives business is scheduled to commence production from new brownfield plant at Jhagadia site in the second half of FY '26 (Naresh Patel, Page 5)

    How to verify

    guidance_and_targets[category='Electrolyte Additives'][metric='Production Commencement']

    Risks & concerns

    4
    RiskSeverity

    Global economic uncertainty and geopolitical dynamics

    Shifting geopolitical dynamics and evolving policy decisions create significant uncertainty for the global economy.Management acknowledged

    medium

    U.S. tariff framework for chemicals

    The unfolding U.S. tariff framework could lead to fluctuations in raw material and finished goods prices, impacting the highly dynamic chemicals market.Management acknowledged

    medium

    Subdued demand for legacy semiconductors

    Demand for semiconductors in cars, industrial equipment, and other devices has been subdued in recent months, impacting the Baba Fine Chem business.Management acknowledged

    medium

    Seasonal weakness in Q1/H1

    Q1 is typically the weakest quarter, leading to softer H1 revenue and lower margins due to business cycle patterns.Management acknowledged

    low

    Q&A highlights

    8

    “But it is very difficult for us to share the number of products at this stage. As and when it gets completed, we will update you. ... On the semiconductor business side, the seeding is going on. We are targeting or we are expanding our reach into newer geography of Taiwan, Korea and Japan. This is already going well with a new customer onboarding. (Management, Page 7)”

    Analyst sought specific numbers for CDMO pipeline and semiconductor scale-up, but management provided qualitative updates, citing confidentiality and time for approvals.

    asked by Sudarshan Padmanabhan

    3 min read7 chapters

    Detailed Narrative

    01

    Strong Financial Performance in Q4 and FY25

    Acutaas Chemical delivered a robust performance in Q4 FY25, with revenue growing 37.1% YoY to INR308.5 crores. Gross profit increased by 62.3% YoY to INR146 crores, leading to a gross margin of 47.3%. EBITDA for the quarter nearly doubled YoY to INR85 crores, with the EBITDA margin expanding by 835 bps YoY to 27.5%. For the full year FY25, the company crossed the INR1,000 crore revenue milestone, achieving INR1,006.9 crores, a 40.3% YoY growth, and PAT of INR160.4 crores, almost double the previous year.

    02

    Rebranding to Acutaas Chemicals Limited

    To reflect its enlarged vision and diversified specialty chemicals portfolio, Ami Organics Limited announced its strategic decision to rename the company to Acutaas Chemicals Limited. This rebranding aims to honor its commitment to serving various industries including pharmaceutical, semiconductor, battery chemicals, petroleum, agrochemicals, cosmetics, and preservatives, while emphasizing its dedication to sustainable practices and humanity.

    03

    CDMO Business Momentum and Pipeline

    The CDMO business remains a key growth driver, with management targeting INR1,000 crores in revenue from this segment by FY28. The company reported a 50% YoY growth in its Pharma Intermediates business for FY25, reaching INR854 crores. Several molecules within the core generic intermediates portfolio are expected to benefit from patent expirations in 2025 and 2026, further bolstering growth momentum.

    04

    Electrolyte Additives Business Development

    The electrolyte additives business is on track, with production scheduled to commence from the new brownfield plant at Jhagadia site in H2 FY26. The plant will have a capacity of 2,000 metric tons each for VC and FEC. Management expects this segment to scale up and reach optimum capacity utilization within three years, contributing significantly to future revenue streams. A total capex of INR170 crores is allocated for this project, with INR35 crores already incurred.

    05

    Semiconductor Segment Recovery and Expansion

    Despite subdued demand for legacy semiconductors, the company is actively expanding its reach in new geographies like Taiwan, Korea, and Japan, with new customer onboarding. The existing Baba Fine Chem business is being revamped, and management expects revenue visibility to ramp up in the next 1-2 years. The semiconductor business is seen as a pivotal role in future growth, though it requires time for approvals.

    06

    Capital Expenditure and Debt-Free Funding

    The company incurred INR195 crores in capex for FY25, primarily for the Ankleshwar site, solar projects, and electrolyte additive projects. For FY26, capex is projected to be around INR200 crores, including spillover for electrolyte additives (INR130 crores) and maintenance/pilot plant (INR70 crores). Acutaas Chemical remains debt-free, with INR249 crores in net cash and cash equivalents, and plans to fund all upcoming capex through QIP proceeds and internal accruals.

    07

    Continuous Flow Chemistry Advancements

    Acutaas Chemical has made significant progress in continuous flow chemistry over the last four years, converting several chemistries like esterification, chlorination, and diazotization. Capacities have been scaled up from 10 metric tons to 100 metric tons, with photo chlorination capacity reaching 1,000 metric tons. Some of these chemistries are already commercially operated, while others are under installation, indicating ongoing innovation and efficiency improvements.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.